ENOV · Enovis Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $589.15M | - | $548.91M | $564.54M | $558.83M | - | $505.22M | $525.16M | $516.27M | - |
| Cost of Revenue | $223.67M | - | $220.00M | $229.85M | $226.60M | - | $218.76M | $236.28M | $218.37M | - |
| Gross Profit | $365.49M | - | $328.91M | $334.70M | $332.23M | - | $286.46M | $288.88M | $297.90M | - |
| R&D | $31.53M | - | $29.74M | $30.70M | $28.53M | - | $20.49M | $23.48M | $23.38M | - |
| SG&A | $282.81M | - | $263.62M | $267.07M | $269.02M | - | $249.85M | $264.10M | $255.69M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $73.36M | - | - | - | $71.44M | - | - | - | $6.43M | - |
| Operating Income | $6.53M | - | ($558.49M) | ($16.80M) | ($46.77M) | - | ($31.74M) | ($44.22M) | ($35.01M) | - |
| Interest Expense | $9.17M | - | $8.83M | $9.29M | $9.19M | - | $11.07M | $16.97M | $20.00M | - |
| Income Tax | $9.04M | - | $4.00M | $10.80M | ($1.77M) | - | ($9.10M) | ($8.91M) | ($7.40M) | - |
| Net Income | ($8.76M) | - | ($571.15M) | ($36.74M) | ($55.97M) | - | ($31.52M) | ($18.64M) | ($72.00M) | - |
| EPS - Basic | ($0.15) | - | ($9.99) | ($0.64) | ($0.98) | - | ($0.05) | ($0.34) | ($1.32) | - |
| EPS - Diluted | ($0.15) | - | ($9.99) | ($0.64) | ($0.98) | - | ($0.58) | ($0.34) | ($1.32) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $33.13M | $36.39M | $33.62M | $44.07M | $38.46M | $48.17M | $35.42M | $35.00M | $66.27M | $36.19M |
| Accounts Receivable | $444.21M | $442.79M | $431.77M | $453.70M | $435.62M | $407.03M | $400.22M | $394.74M | $381.05M | $291.48M |
| Inventory | $602.54M | $584.38M | $613.75M | $628.22M | $585.91M | $547.12M | $609.66M | $615.04M | $586.00M | $468.83M |
| Accounts Payable | $213.62M | $187.53M | $198.78M | $212.02M | $188.15M | $179.10M | $158.04M | $159.83M | $155.75M | $132.47M |
| Current Assets | $1.24B | $1.21B | $1.28B | $1.28B | $1.22B | $1.15B | $1.20B | $1.17B | $1.15B | $896.52M |
| Total Assets | $3.83B | $3.83B | $4.43B | $5.02B | $4.88B | $4.72B | $5.55B | $5.44B | $5.48B | $4.51B |
| Current Liabilities | $608.66M | $598.47M | $575.44M | $568.18M | $477.42M | $529.00M | $530.22M | $518.00M | $549.13M | $369.61M |
| Long-term Debt | $1.29B | $1.26B | $1.34B | $1.37B | $1.37B | $1.31B | $1.33B | $1.33B | $1.32B | $466.16M |
| Total Liabilities | $2.35B | $2.34B | $2.41B | $2.44B | $2.25B | $2.15B | $2.22B | $2.15B | $2.17B | $1.09B |
| Stockholders' Equity | $1.48B | $1.49B | $2.02B | $2.58B | $2.62B | $2.56B | $3.33B | $3.29B | $3.31B | $3.42B |
| Retained Earnings | ($1.48B) | ($1.47B) | ($946.87M) | ($375.73M) | ($338.99M) | ($283.02M) | $420.31M | $451.83M | $470.47M | $542.47M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $23.95M | - | - | - | ($1.60M) | - | - | - | ($36.16M) | - |
| Investing Cash Flow | ($53.09M) | - | - | - | ($60.52M) | - | - | - | ($797.84M) | - |
| Financing Cash Flow | $26.02M | - | - | - | $51.19M | - | - | - | $864.54M | - |
| CapEx | $52.80M | - | - | - | $43.26M | - | - | - | $36.93M | - |
| Free Cash Flow | ($28.85M) | - | - | - | ($44.86M) | - | - | - | ($73.08M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 62.0% | - | 59.9% | 59.3% | 59.5% | - | 56.7% | 55.0% | 57.7% | - |
| Operating margin | 1.1% | - | -101.7% | -3.0% | -8.4% | - | -6.3% | -8.4% | -6.8% | - |
| EBITDA margin | 13.6% | - | - | - | 4.4% | - | - | - | -5.5% | - |
| Net margin | -1.5% | - | -104.1% | -6.5% | -10.0% | - | -6.2% | -3.5% | -13.9% | - |
| Free cash flow margin | -4.9% | - | - | - | -8.0% | - | - | - | -14.2% | - |
| FCF / Net income | 3.29 | - | - | - | 0.80 | - | - | - | 1.02 | - |
| R&D / Revenue | 5.4% | - | 5.4% | 5.4% | 5.1% | - | 4.1% | 4.5% | 4.5% | - |
| SG&A / Revenue | 48.0% | - | 48.0% | 47.3% | 48.1% | - | 49.5% | 50.3% | 49.5% | - |
| Effective tax rate | 3218.9% | - | - | - | - | - | - | - | - | - |
| Return on assets | -0.2% | - | -12.9% | -0.7% | -1.1% | - | -0.6% | -0.3% | -1.3% | - |
| Return on equity | -0.6% | - | -28.3% | -1.4% | -2.1% | - | -0.9% | -0.6% | -2.2% | - |
| Return on invested capital | 0.1% | - | -13.1% | -0.3% | -0.9% | - | -0.5% | -0.8% | -0.6% | - |
| Liquidity | ||||||||||
| Current ratio | 2.04 | 2.02 | 2.22 | 2.25 | 2.55 | 2.17 | 2.27 | 2.26 | 2.10 | 2.43 |
| Quick ratio | 1.05 | 1.04 | 1.16 | 1.15 | 1.32 | 1.13 | 1.12 | 1.08 | 1.03 | 1.16 |
| Cash ratio | 0.05 | 0.06 | 0.06 | 0.08 | 0.08 | 0.09 | 0.07 | 0.07 | 0.12 | 0.10 |
| Leverage | ||||||||||
| Debt / Equity | 0.87 | 0.85 | 0.66 | 0.53 | 0.52 | 0.51 | 0.40 | 0.40 | 0.40 | 0.14 |
| Debt / Assets | 0.34 | 0.33 | 0.30 | 0.27 | 0.28 | 0.28 | 0.24 | 0.24 | 0.24 | 0.10 |
| Debt / EBITDA | 16.16 | - | - | - | 55.44 | - | - | - | - | - |
| Interest coverage | 0.7x | - | -63.3x | -1.8x | -5.1x | - | -2.9x | -2.6x | -1.8x | - |
| Equity multiplier | 2.59 | 2.57 | 2.19 | 1.95 | 1.86 | 1.84 | 1.67 | 1.66 | 1.66 | 1.32 |
| Liabilities / Assets | 0.61 | 0.61 | 0.54 | 0.49 | 0.46 | 0.46 | 0.40 | 0.40 | 0.40 | 0.24 |
| Efficiency | ||||||||||
| Asset turnover | 0.15 | - | 0.12 | 0.11 | 0.11 | - | 0.09 | 0.10 | 0.09 | - |
| Inventory turnover | 0.37 | - | 0.36 | 0.37 | 0.39 | - | 0.36 | 0.38 | 0.37 | - |
| Days sales outstanding | 275d | - | 287d | 293d | 285d | - | 289d | 274d | 269d | - |
| Days inventory outstanding | 983d | - | 1018d | 998d | 944d | - | 1017d | 950d | 979d | - |
| Days payable outstanding | 349d | - | 330d | 337d | 303d | - | 264d | 247d | 260d | - |
| Cash conversion cycle | 910d | - | 976d | 954d | 925d | - | 1043d | 978d | 989d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.9x | - | 0.9x | 0.7x | 0.7x | - | 0.7x | 0.8x | 1.0x | - |
| P / S | 2.2x | - | 3.3x | 3.4x | 3.3x | - | 4.8x | 4.7x | 6.6x | - |
| EV / EBITDA | 32.0x | - | - | - | 128.8x | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 5.4% | - | 8.6% | 7.5% | 8.2% | - | 21.0% | 22.6% | 27.1% | - |
| Revenue CAGR (3y) | 13.2% | - | 12.7% | 12.6% | -18.3% | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | -7.4% | -1.9% | -7.3% | - | -9.8% | -10.4% | -10.1% | - |
| Gross profit growth (YoY) | 10.0% | - | 14.8% | 15.9% | 11.5% | - | 17.9% | 16.3% | 26.7% | - |
| Operating income growth (YoY) | - | - | -1659.7% | 62.0% | -33.6% | - | -54.9% | -205.1% | -40.2% | - |
| Net income growth (YoY) | 84.3% | - | -1712.0% | -97.1% | 22.3% | - | -994.5% | -86.5% | - | - |
| EPS growth (YoY) | 84.7% | - | -1622.4% | -88.2% | 25.8% | - | -1060.0% | -88.9% | -207.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 35.7% | - | - | - | 38.6% | - | - | - | -218.0% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -43.6% | -41.9% | -39.3% | -21.6% | -20.9% | -25.0% | -3.2% | -4.7% | -3.9% | -0.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$2.25B totalPrevention And Recovery$1.14B · 50.6%
Reconstructive Segment$1.11B · 49.4%
Product / service
$1.67B totalSurgical$537.46M · 32.1%
Bracing And Support$486.24M · 29.0%
Prevention And Recovery$379.09M · 22.6%
Other Prevention And Recovery$271.63M · 16.2%
Geographic
$2.25B totalUS$1.30B · 57.6%
Foreign$952.72M · 42.4%
Peer comparison
Same SIC group: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Comparing Enovis CORP against the 5 most active filers in the same SIC group.